Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06024772 · ClinicalTrials.gov registry record · Phase 3
Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer
A Phase 3 study, sponsored by Thomas Jefferson University.
- Not yet
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT06024772: Clinical Trial Phase 3 study, sponsored by Thomas Jefferson University.
NCT06024772 is a Phase 3 study that has not yet begun recruiting, run by Thomas Jefferson University. The registered enrollment target is 300 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06024772, a Phase 3 study, has not yet begun recruiting, sponsored by Thomas Jefferson University.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
This phase III trial compares the use of contrast-enhanced multiparametric ultrasound (mp-US) to multiparametric magnetic resonance imaging (mp-MRI) for the diagnosis of clinically significant prostate cancer (PCa). A mp-US is a procedure in which a probe that sends out high-energy sound waves is inserted into the rectum. The sound waves are bounced off internal tissues or organs and make echoes. The echoes form a picture of body tissue called a sonogram. Perflutren lipid michrosphere (Definity) is a contrast agent that uses microbubbles to enhance ultrasound images of the prostate. Doctors hope to learn if the Definity-enhanced mp-US imaging technique can accurately direct targeted biopsy for the detection of clinically significant prostate cancer when compared to standard of care mp-MRI.
Primary Outcome
Will compare PCa detection rate of 3D mp-US combined with systematic biopsy to detection rate of multiparametric magnetic resonance imaging (mp-MRI) combined with systematic biopsy. Will evaluate paired biopsy data for non-inferiority and superiority endpoints, comparing the detection rate of clinically significant PCa with mp-US + systematic biopsy to the detection rate of mp-MRI + systematic biopsy. This analysis will be repeated using both definitions of clinically significant PCa. Categorica
Interventions
- PROCEDURE Biopsy of Prostate
- PROCEDURE Transrectal Ultrasound
- DRUG Perflutren lipid microsphere
- PROCEDURE ultiparametric Magnetic Resonance Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-02 |
| Phase | Phase 3 |
What is known before NCT06024772 opens enrollment
NCT06024772 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 4 interventions - of which Biopsy of Prostate is the first listed.
NCT06024772 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06024772 about?
NCT06024772 is a clinical study titled "Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer". This phase III trial compares the use of contrast-enhanced multiparametric ultrasound (mp-US) to multiparametric magnetic resonance imaging (mp-MRI) for the diagnosis of clinically significant prostate cancer (PCa). A mp-US is a procedure in which a probe that sends out high-energy sound waves is in...
What is the current status of trial NCT06024772?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-07. Estimated completion is 2027-02.
What interventions are being tested in trial NCT06024772?
The interventions under investigation include: Biopsy of Prostate (PROCEDURE), Transrectal Ultrasound (PROCEDURE), Perflutren lipid microsphere (DRUG), ultiparametric Magnetic Resonance Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT06024772?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06024772's enrollment target sits among peer trials
300 1122nd of 2000 higher than 840 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia